These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 20460631)

  • 1. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

  • 2. INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.
    Govindan R
    J Clin Oncol; 2010 Feb; 28(5):713-5. PubMed ID: 20038722
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
    Ou SH; Bazhenova L; Camidge DR; Solomon BJ; Herman J; Kain T; Bang YJ; Kwak EL; Shaw AT; Salgia R; Maki RG; Clark JW; Wilner KD; Iafrate AJ
    J Thorac Oncol; 2010 Dec; 5(12):2044-6. PubMed ID: 21102269
    [No Abstract]   [Full Text] [Related]  

  • 4. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
    Gilbert JA
    Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
    [No Abstract]   [Full Text] [Related]  

  • 5. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
    Costa DB
    J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
    [No Abstract]   [Full Text] [Related]  

  • 6. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.
    Yamamoto S; Korn RL; Oklu R; Migdal C; Gotway MB; Weiss GJ; Iafrate AJ; Kim DW; Kuo MD
    Radiology; 2014 Aug; 272(2):568-76. PubMed ID: 24885982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
    Giroux Leprieur E; Wislez M
    Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-small cell lung cancer--genetic predictors.
    Koudelakova V; Kneblova M; Trojanec R; Drabek J; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):125-36. PubMed ID: 23733083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 11. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
    Rosell R; Karachaliou N; Wolf J; Ou SH
    Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349
    [No Abstract]   [Full Text] [Related]  

  • 12. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
    Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G
    J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444
    [No Abstract]   [Full Text] [Related]  

  • 13. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
    Shaw AT
    Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
    Toyokawa G; Hirai F; Inamasu E; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
    J Thorac Oncol; 2014 Dec; 9(12):e86-7. PubMed ID: 25393798
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
    Cottini F; Lautenschlaeger T
    Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROS1 [corrected].
    Pal P; Khan Z
    J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular pathology of lung cancer: key to personalized medicine].
    Cheng L; Li Y; Zhang SB; Teng XD
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
    [No Abstract]   [Full Text] [Related]  

  • 18. Activation of RAS family members confers resistance to ROS1 targeting drugs.
    Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
    Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 20. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.